Synopsis
Synopsis
0
USDMF
0
CEP/COS
0
JDMF
0
EU WC
0
KDMF
0
VMF
0
FDF
0
Europe
0
Canada
0
Australia
0
South Africa
0
Listed Dossiers
DRUG PRODUCT COMPOSITIONS
0
EDQM
0
USP
0
JP
0
Others
0
Stock Recap #PipelineProspector
0
Weekly News Recap #Phispers
US Medicaid
NA
Annual Reports
NA
Finished Drug Prices
NA
1. (1,1'-biphenyl)-2-sulfonamide, 4'-((2-butyl-4-oxo-1,3-diazaspiro(4.4)non-1-en-3-yl)methyl)-n-(4,5-dimethyl-3-isoxazolyl)-2'-(ethoxymethyl)-
2. 4'-((2-butyl-4-oxo-1,3-diazaspiro(4.4)non-1-en-3-yl)methyl)-n-(4,5-dimethyl-1,2-oxazol-3-yl)-2'-(ethoxymethyl)-2-biphenylsulfonamide
3. 4'-((2-butyl-4-oxo-1,3-diazaspiro(4.4)non-1-en-3-yl)methyl)-n-(4,5-dimethyl-1,2-oxazol-3-yl)-2'-(ethoxymethyl)biphenyl-2-sulfonamide
4. Re-021
1. 254740-64-2
2. Sparsentan (re-021)
3. Re-021
4. Sparsentan [usan]
5. Ps433540
6. Ps-433540
7. 9242ro5urm
8. Chembl539423
9. 2-[4-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-2-(ethoxymethyl)phenyl]-n-(4,5-dimethyl-1,2-oxazol-3-yl)benzenesulfonamide
10. 4'-((2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl)-n-(4,5-dimethylisoxazol-3-yl)-2'-(ethoxymethyl)-[1,1'-biphenyl]-2-sulfonamide
11. Retrophin
12. (1,1'-biphenyl)-2-sulfonamide, 4'-((2-butyl-4-oxo-1,3-diazaspiro(4.4)non-1-en-3-yl)methyl)-n-(4,5-dimethyl-3-isoxazolyl)-2'-(ethoxymethyl)-
13. [1,1'-biphenyl]-2-sulfonamide, 4'-[(2-butyl-4-oxo-1,3-diazaspiro[4.4]non-1-en-3-yl)methyl]-n-(4,5-dimethyl-3-isoxazolyl)-2'-(ethoxymethyl)-
14. Unii-9242ro5urm
15. Dara
16. Compound 7 [pmid 15634011]
17. Dara-a
18. Ps 33540
19. Sparsentan [inn]
20. Sparsentan (usan/inn)
21. Sparsentan(ps433540)
22. Sparsentan [who-dd]
23. Schembl535109
24. Gtpl8448
25. Amy38147
26. Bcp23969
27. Ex-a3048
28. Bdbm50175523
29. S6665
30. Cs-7947
31. Db12548
32. Sb16876
33. Dara-a (dual Acting Receptor Antagonist Of Angiotension And Endothelin Receptors)
34. Ps-433540;re-021;dara
35. Ac-35179
36. Hy-17621
37. Sparsentan (ps-433540,re-021,dara)
38. D11776
39. F77045
40. A858308
41. L023324
42. Q27088845
43. 4''''-(2-butyl-4-oxo-1,3-diaza-spiro[4.4]non-1-en-3-ylmethyl)-2''''-ethoxymethyl-biphenyl-2-sulfonic Acid (4,5-dimethyl-isoxazol-3-yl)-amide
44. 4''-(2-butyl-4-oxo-1,3-diaza-spiro[4.4]non-1-en-3-ylmethyl)-2''-ethoxymethyl-biphenyl-2-sulfonic Acid (4,5-dimethyl-isoxazol-3-yl)-amide
45. 4'-((2-butyl-4-oxo-1,3-diazaspiro(4.4)non-1-en-3-yl)methyi)-n-(4,5- Dimethylisoxazol-3-yl)-2'-(ethoxymethyl)biphenyl-2-sulfonamide
46. 4'-((2-butyl-4-oxo-1,3-diazaspiro(4.4)non-1-en-3-yl)methyl)-n-(4,5-dimethyl-1,2-oxazol-3-yl)-2'-(ethoxymethyl)-2-biphenylsulfonamide
47. 4'-((2-butyl-4-oxo-1,3-diazaspiro(4.4)non-1-en-3-yl)methyl)-n-(4,5-dimethyl-1,2-oxazol-3-yl)-2'-(ethoxymethyl)biphenyl-2-sulfonamide
Molecular Weight | 592.8 g/mol |
---|---|
Molecular Formula | C32H40N4O5S |
XLogP3 | 5 |
Hydrogen Bond Donor Count | 1 |
Hydrogen Bond Acceptor Count | 8 |
Rotatable Bond Count | 12 |
Exact Mass | 592.27194156 g/mol |
Monoisotopic Mass | 592.27194156 g/mol |
Topological Polar Surface Area | 123 Ų |
Heavy Atom Count | 42 |
Formal Charge | 0 |
Complexity | 1060 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 0 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 1 |
Treatment of focal segmental glomerulosclerosis
Treatment of primary IgA nephropathy
Sparsentan, which possesses two clinically validated mechanisms of action in a single molecule, works by selectively blocking the action of two potent vasoconstrictor and mitogenic agents, angiotensin II (AII) and endothelin 1 (ET1), at their respective receptors. Sparsentan is highly selective (10,000-fold) for the AII receptor sub-type 1 and the ET receptor sub-type A. As such, Sparsentan combines the properties of an angiotensin receptor blocker (ARB) and an endothelin receptor antagonist (ERA) in the same molecule.
Market Place
Patents & EXCLUSIVITIES
ABOUT THIS PAGE
A Sparsentan manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Sparsentan, including repackagers and relabelers. The FDA regulates Sparsentan manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Sparsentan API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.
click here to find a list of Sparsentan manufacturers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PhamaCompass.
A Sparsentan supplier is an individual or a company that provides Sparsentan active pharmaceutical ingredient (API) or Sparsentan finished formulations upon request. The Sparsentan suppliers may include Sparsentan API manufacturers, exporters, distributors and traders.
click here to find a list of Sparsentan suppliers with USDMF, JDMF, KDMF, CEP, GMP, COA and API Price related information on PharmaCompass.
National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Sparsentan as an active pharmaceutical ingredient (API).
The FDA updates the NDC directory daily. The NDC numbers for Sparsentan API and other APIs are published in this directory by the FDA.
The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.
Pharmaceutical companies that manufacture Sparsentan as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.
The NDC directory also contains data on finished compounded human drug products that contain Sparsentan and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Sparsentan NDC to their finished compounded human drug products, they may choose to do so.
click here to find a list of Sparsentan suppliers with NDC on PharmaCompass.
Sparsentan Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.
GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).
PharmaCompass offers a list of Sparsentan GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, API price, and more, enabling you to easily find the right Sparsentan GMP manufacturer or Sparsentan GMP API supplier for your needs.
A Sparsentan CoA (Certificate of Analysis) is a formal document that attests to Sparsentan's compliance with Sparsentan specifications and serves as a tool for batch-level quality control.
Sparsentan CoA mostly includes findings from lab analyses of a specific batch. For each Sparsentan CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.
Sparsentan may be tested according to a variety of international standards, such as European Pharmacopoeia (Sparsentan EP), Sparsentan JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Sparsentan USP).
LOOKING FOR A SUPPLIER?